" /> Ibrutinib - CISMeF





Preferred Label : Ibrutinib;

NCIt synonyms : BTK Inhibitor PCI-32765; 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-;

NCIt definition : An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.;

UNII : 1X70OSD4VX;

InChIKey : XYFPWWZEPKGCCK-GOSISDBHSA-N;

CAS number : 936563-96-1;

Drug name : Imbruvica;

Molecule name : PCI-32765; CRA-032765; CRA 032765; PCI 32765;

Chemical formula : C25H24N6O2;

Codes from synonyms : 263;

Détails


Position du mot-clé dans l'(les) arborescence(s) : arborescence

Vous pouvez consulter :


Nous contacter.
31/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.